{
  "trial_id": "NCT01539083",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Previously diagnosed with multiple myeloma based on international myeloma working group (IMWG) criteria.",
      "label": "met"
    },
    {
      "criterion": "Serum M-protein greater than or equal to (>=) 1 gram per deciliter (g/dL) (>=10 gram per liter);",
      "label": "met"
    },
    {
      "criterion": "Urine M-protein >=200 milligram (mg) per 24 hour and Serum Free Light chain (FLC) assay: Involved FLC Level >=10 mg/dL (>=100 mg/L) provided serum FLC ratio is normal;",
      "label": "met"
    },
    {
      "criterion": "Meet the pretreatment laboratory criteria as specified in the study protocol at and within 21 days before baseline (Day 1 of Cycle 1, before bortezomib administration for induction).",
      "label": "met"
    },
    {
      "criterion": "Have ECOG status 0-2.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Has previously received treatment for multiple myeloma (including prior therapy with radiation or pulsed dexamethasone) as specified in the study protocol.",
      "label": "does_not_trigger"
    },
    {
      "criterion": "Has a history of any other malignancy within 5 years before enrolment as specified in the study protocol.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has multiple myeloma with recurrent disease and systemic amyloidosis, on hemodialysis for ESRD. She was treated with various regimens including melphalan, prednisone, VAD, thalidomide, and velcade.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01539083",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}